The pseudogene DUXAP10 contributes to gefitinib resistance in NSCLC by repressing OAS2 expression

The pseudogene DUXAP10 contributes to gefitinib resistance in NSCLC by repressing OAS2 expression

Gefitinib, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI),is the currently recommended first-line therapy for advanced EGFR-mutant lung cancer, and understanding the mechanism of resistance is the key to formulating therapeutic strategies for EGFR-TKIs. In this study, we ev...

Full description

Bibliographic Details
Main Authors: Ren Shengnan, Zhu Ya, Wang Siying, Zhang Qinqiu, Zhang Niu, Zou Xiaoteng, Wei Chenchen, Wang Zhaoxia
Format: Article
Language:English
Published: China Science Publishing & Media Ltd. 2022-11-01
Series:Acta Biochimica et Biophysica Sinica
Subjects:
NSCLC
gefitinib resistance
DUXAP10
EZH2
OAS2
Online Access:https://www.sciengine.com/doi/10.3724/abbs.2022176

Similar Items

Similar Items